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H E A L T H  A N D  M E D I C I N E
Anti-CotH3 antibodies protect mice from  
mucormycosis by prevention of invasion and 
augmenting opsonophagocytosis
Teclegiorgis Gebremariam1, Sondus Alkhazraji1, Sameh S. M. Soliman2, Yiyou Gu1,  
Heewon H. Jeon1, Lina Zhang1,3, Samuel W. French1,4, David A. Stevens5,6, John E. Edwards Jr.1,7,  
Scott G. Filler1,7, Priya Uppuluri1,7, Ashraf S. Ibrahim1,7*
Mucorales are fungal pathogens that cause mucormycosis, a lethal angioinvasive disease. Previously, we demon-
strated that Rhizopus, the most common cause of mucormycosis, invades endothelial cells by binding of its CotH 
proteins to the host receptor GRP78. Loss of CotH3 renders the fungus noninvasive and attenuates Rhizopus virulence 
in mice. Here, we demonstrate that polyclonal antibodies raised against peptides of CotH3 protected diabetic 
ketoacidotic (DKA) and neutropenic mice from mucormycosis compared to mice treated with control preimmune 
serum. Passive immunization with anti-CotH3 antibodies enhanced neutrophil inlfux and triggered Fc receptor- 
mediated enhanced opsonophagocytosis killing of Rhizopus delemar. Monoclonal antibodies raised against the 
CotH3 peptide also protected immunosuppressed mice from mucormycosis caused by R. delemar and other Mucorales 
and acted synergistically with antifungal drugs in protecting DKA mice from R. delemar infection. These data identify 
anti-CotH3 antibodies as a promising adjunctive immunotherapeutic option against a deadly disease that often 
poses a therapeutic challenge.
INTRODUCTION
Mucormycosis is a fungal infection with an often fatal prognosis (1, 2). 
Treatment options for the disease are limited, frequently involving 
extensive disfiguring surgical debridement and toxic antifungal 
therapy that, even if effective, frequently lead to a dismal quality of life 
(3). Even with aggressive and optimal current treatment, mortality 
rates for mucormycosis range from 50 to 100%. Higher mortalities are 
seen in patients with prolonged neutropenia, disseminated disease, or 
brain infection (1, 2).
Mucormycosis is caused by several fungi that belong to the order 
Mucorales. These organisms typically cause acute, aggressive, and pre-
dominantly angioinvasive infections in immunocompromised hosts 
with hematologic malignancy and/or stem cell transplantation (1). 
Other high-risk patients include those with poorly controlled hyper-
glycemia, diabetic ketoacidosis (DKA), and other forms of acidosis 
(1, 2). Rhizopus, Mucor, and Lichtheimia are the leading genera of 
fungi that cause mucormycosis, accounting for up to 90% of all cases 
of this disease (1, 2), whereas Apophysomyces, Cunninghamella, and 
Rhizomucor, besides others, cause between 1 and 5% of all reported 
cases (4). These Mucorales can also cause life-threatening infections 
in immunocompetent individuals suffering from severe trauma due 
to natural disasters (5), blast injuries during combat operation (6), 
or motor vehicle accidents (7).
There has been an alarming rise in the incidence of mucormycosis 
at major U.S. transplant centers (8). Mucormycosis is the third most 
common invasive fungal infection in hematopoietic stem cell trans-
plant patients in the United States (9), with prevalence rates of 8% in 
autopsied leukemia patients (10). Similarly, a 70% increase in mu-
cormycosis cases has been reported in France over a 9-year period 
(between 1997 and 2006) (11). Notably, a study reviewing cases in 
India for the past five decades predicted a prevalence of 0.14 cases 
per 1000 population, which equates to ~200,000 cases per year (12). 
Most recently, the number of mucormycosis patients per 10,000 hos-
pital admissions increased substantially between 2008 and 2017 from 
0.47 to 1.18 in a hospital in Lebanon (13).
The treatment of mucormycosis is compromised by the limited 
arsenal of approved effective antifungal drugs, coupled with an in-
herent tendency for these fungi to be drug resistant (14). Only three 
antifungal drugs are currently approved for the treatment of mu-
cormycosis; they are lipid formulations of amphotericin B, posaconazole, 
and isavuconazole (15). In the absence of surgical debridement of 
necrotic tissues at infected foci, antifungal therapy alone is rarely 
curative (16). Thus, alternative strategies to prevent and treat mu-
cormycosis are needed.
Previously, we determined that Rhizopus strains adhere to and 
invade human umbilical vein endothelial cells (HUVECs) in vitro 
by induced endocytosis (17). This fungal-host cell interaction is me-
diated by the fungal cell surface protein CotH (specifically CotH3), 
which binds to the glucose-regulated protein 78 (GRP78) on the 
endothelial cell surface (17, 18). Elevated concentrations of glucose, 
iron, and ketone bodies, which occur in patients with hyperglycemia 
and DKA, enhance GRP78 and CotH3 expression, leading to aug-
mented fungal invasion and damage of HUVECs (18, 19). Corre-
spondingly, repression of CotH3 expression by RNA interference 
abrogates HUVEC invasion and Rhizopus-mediated host cell injury 
and results in significantly reduced virulence in mice (18). CotH 
proteins are highly conserved within the order Mucorales, making 
it a potential therapeutic target (18, 20).
To address the unmet need for novel treatment alternatives against 
mucormycosis, we developed antibodies against peptide regions of 
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CotH3, which are conserved among Mucorales and in the binding 
site to GRP78 (18). We sought to evaluate the potential use of passive 
immunotherapy against Mucorales in mice, using polyclonal and 
monoclonal antibodies directed at this 16-mer peptide. Last, we ex-
amined the mechanism of action of the antibodies in mediating pro-
tection and evaluated their potential utility as adjunctive therapy 
with clinically relevant antifungal drugs. Overall, this work illustrates 
the potential of a new immunotherapeutic modality to combat 
mucormycosis based on a unique protein universally present in 
Mucorales fungi.
RESULTS
Human sera have low natural antibody titers against  
CotH3 protein
We compared the presence of natural anti-CotH3 antibodies in sera 
collected from healthy volunteers who are routinely exposed to Rhizopus 
(member from our laboratory) to sera from patients with mucor-
mycosis using enzyme-linked immunosorbent assay (ELISA) plates 
coated with either recombinant CotH3 protein (rCotH3p) or the 
antigenic, surface-exposed,16-mer peptide (MGQTNDGAYRDPTDNN). 
In general, low and similar titers of anti-CotH3 antibodies were de-
tected in healthy individuals and patients with mucormycosis ranging 
from 1:200 to 1:800 dilution. A single patient had a titer of 1:1600 
(Fig. 1A). Similarly, there was no difference in the low anti–16-mer 
peptide antibody titers between the two subject groups. As expected, 
the titers against the rCotH3p were higher than those against the 
16-mer peptide (Fig. 1A). Concordant with the low antibody titers 
in healthy volunteers, samples taken from the same patient over 2 to 
8 weeks following diagnosis did not show a significant increase in 
antibody titers (Fig. 1A, colored symbols). The results of low titers 
of natural anti-CotH3 antibodies among healthy individuals and 
the lack of increase in anti-CotH3 titers following infection suggested 
that treatment with antibodies targeting an invasin required for 
Fig. 1. CotH antibody titers in mucormycosis patients are not different from those in healthy subjects, while rabbit anti-CotH3 polyclonal antibodies specifically 
bind to Mucorales. (A) ELISA plates coated with rCotH3 from Escherichia coli or the 16-mer peptide showing low and similar anti-CotH3 antibody titers in sera collected 
from mucormycosis patients (11 total) or healthy volunteers (12 total). Colored symbols indicate sera collected from the same patient at different days (numbers) following 
diagnosis (day 0). (B) Flow cytometry analysis revealed that different concentrations of anti-CotH3 polyclonal antibody (and not the preimmune IgG antibody) bound 
both R. delemar spores and germlings with high consistency but not with A. fumigatus. The different doses of antibodies ranged from the highest (100 g/ml) to the lowest 
(3 g/ml). (C) The polyclonal antibodies also bound to a number of other fungi belonging to the order Mucorales.
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mucormycosis pathogenesis is likely to be effective in attenuating 
infections by Mucorales organisms by blocking adherence and in-
vasion of the organisms to host cells.
Polyclonal anti-CotH3 antibodies are promising novel 
therapy against Rhizopus delemar infections
We generated rabbit polyclonal antibodies against two peptides of 
R. delemar CotH3 that are predicted to be antigenic and reside in 
the binding site of the host GRP78 protein (18). In our previous study, 
the CotH3 antibodies prevented R. delemar–mediated invasion and 
subsequent damage of human endothelial cells in vitro and pro-
longed survival of DKA mice with pulmonary mucormycosis due to 
R. delemar. This attenuation of pathogenesis required a high dose of 
antibody, 1 mg per mouse (18). This dose translates to ~2.4 g of 
antibody per patient, an amount that is clinically unprecedented 
and impractical. Consequently, in the current study, we intended to 
further determine the efficacy of the polyclonal antibodies, define 
their mechanism of action in vitro and in vivo, and examine their 
potential transferability as novel therapeutics against mucormycosis.
We began by testing the binding of the polyclonal anti-CotH3 
antibodies to R. delemar spores and germlings. This member of 
Mucorales expresses high levels of CotH mRNA (18, 20). Immuno-
staining of spores and germlings with anti-CotH3 polyclonal antibodies, 
followed by flow cytometry, showed consistent immunoglobulin G 
(IgG) binding to the fungus (Fig. 1B). The lowest (3 g/ml) and the 
highest (100 g/ml) concentrations of the antibodies had almost similar 
total binding to the organism. In contrast, negligible binding was ob-
served in negative control conditions (secondary antibody only) or when 
fungi were treated with preimmune IgG (Fig. 1B). Furthermore, the 
anti-CotH3 antibodies did not bind to Aspergillus fumigatus spores or 
germlings, a mold that has no CotH orthologs. However, the anti- 
CotH3 antibodies had no effect on the growth or germination of 
R. delemar, as indicated by the lack of effect of anti- CotH3 antibodies 
on germ tube length or metabolic activity of the fungus (fig. S1).
Next, we determined whether polyclonal antibodies were pro-
tective in neutropenic mice at lower and clinically translational doses. 
Neutropenic mice were intratracheally infected with R. delemar and 
then, 24 hours later, treated intraperitoneally with a single dose of 
30, 100, or 300 g of purified rabbit anti-CotH3 IgG or isotype- 
matched IgG purified from preimmune serum (control). All mice 
treated with preimmune purified IgG expired by day 8 after infec-
tion, resulting in a median survival time of 5 days. In contrast, mice 
treated with 30, 100, or 300 g of anti-CotH3 IgG had prolonged 
survival of 70, 30, and 40%, respectively (P < 0.05 for anti-CotH3 
IgG versus preimmune IgG at all doses; Fig. 2A). The differences in 
survival among the different doses of anti-CotH3 IgG-treated mice 
were not significant (P = 0.07 for 30 g versus 100 g and P = 0.17 
for 30 g versus 300 g). Surviving mice were healthy by day 21 
when the experiment was terminated.
In a separate study, neutropenic mice were infected and treated 
as above and then euthanized 48 hours after treatment, and their 
target organs (lungs and brain) were collected for tissue fungal burden 
analysis. Anti-CotH3 antibodies reduced the lung fungal burden by 
>1 log and almost completely abrogated the ability of R. delemar to 
hematogenously disseminate to the brain [a secondary target organ 
in this model (21)] (Fig. 2B). Consistent with these results, histo-
pathological examination of the lungs revealed extensive hemorrhage 
and tissue edema in mice infected with R. delemar and treated with 
control IgG, while the lungs harvested from infected mice treated 
with the anti-CotH3 IgG had a more normal organ architecture 
(Fig. 2C, top). On a higher magnification, numerous broad, ribbon- 
like, and aseptate hyphae with 90° angle bifurcation were present in 
mice treated with control preimmune IgG, whereas very few fungal 
elements were present in the lungs of mice treated with anti-CotH3 
IgG (Fig. 2C, middle). Furthermore, in mice treated with control 
IgG, fungal cells were present in thrombosed cerebral blood vessels 
with hyphae egressing to seed the tissue parenchyma (Fig. 2C, bot-
tom). In contrast, the brains harvested from mice treated with anti- 
CotH3 IgG had little evidence of infection and no angioinvasion.
To further confirm the therapeutic potential of anti-CotH3 anti-
bodies, we tested the lower and most protective dose of the antibodies 
in the DKA model of pulmonary mucormycosis. Infection with 
R. delemar, followed by treatment with anti-CotH3 IgG (30 g), was 
conducted as above. While DKA mice treated with preimmune IgG 
had 100% mortality by day 13 after infection, 60% of mice treated 
with anti-CotH3 IgG survived the infection. The surviving mice ap-
peared healthy by day 21 (Fig. 2D). Last, anti-CotH3 IgG treatment 
caused reduction of at least 1.5 log when compared to mice treated 
with isotype-matched control IgG (Fig. 2E). Overall, the protective 
effect of low doses of these antibodies in animal models confirms 
their translational potential as a novel treatment for R. delemar– 
associated pneumonia in different hosts (neutropenic and diabetic). 
Further, anti-CotH3 antibodies prevented host cell invasion and hem-
atogenous dissemination to secondary target organs.
Anti-CotH3 antibodies protect against mucormycosis caused 
by other Mucorales
Querying peptide MGQTNDGAYRDPTDNN against 38 Mucorales 
genomes [sequenced by us and others (all raw sequencing data are 
from the National Center for Biotechnology Information Sequence 
Read Archive database)] (20) revealed the universal presence of CotH 
among these fungi with a high degree of predicted amino acid iden-
tity (73 to 100% with one to seven copy numbers) (20). This peptide 
was also found to be highly conserved among Mucorales with 71 to 
100% amino acid identity (table S1). Consequently, we hypothesized 
that the polyclonal antibodies should recognize CotH proteins on 
Mucorales fungi other than R. delemar. Immunostaining of Rhizopus 
oryzae, Lichtheimia corymbifera, Cunninghamella bertholletiae, Mucor 
circinelloides, Mucor ramosissimus, and Rhizomucor spp. showed robust 
binding of the anti-CotH3 antibodies to the germlings of these highly 
pathogenic Mucorales, while the preimmune IgG did not (Fig. 1C).
Given that the polyclonal anti-CotH3 antibodies bound several 
members of the Mucorales order, we posited that these antibodies 
would also protect mice from Mucorales other than R. delemar. Thus, 
we infected neutropenic mice intratracheally with five different 
Mucorales and, 24 hours after infection, treated them with a single 
intraperitoneal dose of 30 g of purified anti-CotH3 IgG or the same 
amount of preimmune IgG. The antibodies significantly reduced 
mortality in mice infected with fungi tested, with the highest level of 
protection observed in mice infected with Rhizomucor and Apophysomyces 
(40 to 60% survival) (Fig. 3). Therefore, the anti-CotH3 antibodies 
protect against >95% of organisms causing mucormycosis.
Anti-CotH3 antibodies augment polymorphonuclear leukocyte–
mediated damage of R. delemar via opsonophagocytosis
We next performed a series of experiments to investigate whether 
anti-CotH3 antibodies enhance polymorphonuclear leukocyte (PMN)– 
mediated killing of R. delemar in vivo. We first examined the role of 
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PMNs in the antibody-mediated clearance of the fungus. Recruit-
ment and activation of PMNs reflects a primary immunological 
response to invading pathogens and is a hallmark of vascular inflam-
mation. One of the key enzymes released upon PMN activation is 
myeloperoxidase (MPO), a heme protein that neutralizes nitric oxide– 
dependent signaling cascades within the vasculature (22). Thus, we 
measured the effects of treatment with control or anti-CotH3 anti-
bodies on the levels of MPO in organs of DKA mice (because these 
mice are not neutropenic) infected with R. delemar. The anti-CotH3 
IgG significantly increased the MPO content of the lungs and spleen 
relative to the control IgG. As expected, the greatest increase in MPO 
occurred in the lungs, which are the primary target organ and spleen, 
which contains larger numbers of PMNs (23), with a 10-fold in-
crease in both organs as compared to mice treated with control 
(Fig. 4A). Treatment with the anti-CotH3 antibodies did not sig-
nificantly increase the MPO levels in the brain, likely because the 
antibodies prevented hematogenous dissemination, leading to a 
very low brain fungal burden (Fig. 2).
Next, we assessed whether the anti-CotH3 antibodies enhanced 
the phagocytosis of R. delemar ex vivo. PMNs from normal or DKA 
mice were isolated and tested for their capacity to phagocytose 
R. delemar in the presence of control or the anti-CotH3 IgG. We 
found that the anti-CotH3 antibodies significantly enhanced the 
phagocytosis of R. delemar spores in both normal and DKA mice 
(Fig. 4B). The anti-CotH3 IgG also augmented the capacity of PMN 
of DKA mice to inhibit the metabolic activity of R. delemar, in con-
trast to the control IgG (Fig. 4C). Furthermore, the anti-CotH3 IgG 
enhanced the ability of murine peritoneal macrophages to kill 
R. delemar spores (5:1 multiplicity of infection, macrophages/ 
R. delemar) ex vivo relative to the control IgG (P < 0.0002; fig. S2A).
We also investigated the mechanism by which the anti-CotH3 IgG 
enhanced R. delemar phagocytosis and growth inhibition. We stained 
murine PMNs with LysoTracker Red before incubating them with 
R. delemar in the presence or absence of the control or anti-CotH3 
IgG. LysoTracker Red is a fluorescent dye that stains the acidic 
compartments in live cells, enabling tracking of phagolysosome 
maturation (24). Acidic organelles could only be detected when 
PMNs were incubated with R. delemar in the presence of anti- 
CotH3 IgG, indicating that enhanced phagocytosis of fungal spores 
in the presence of anti-CotH3 antibodies leads to maturation of the 
phagolysosome (Fig. 4D). Similar results occurred for peritoneal 
murine macrophage incubated with anti-CotH3 IgG (fig. S2B).
To determine whether the enhanced metabolic inhibition of 
R. delemar by murine PMN in the presence of the anti-CotH3 IgG 
was due to killing by reactive oxygen species (ROS), we measured 
ROS release using dihydrorhodamine (DHR) 123. This dye is oxidized 
Fig. 2. Anti-CotH3 polyclonal antibodies protect mice from R. delemar intratracheal infection. Intraperitoneal treatment with a single dose of the polyclonal anti-
body (Ab), 24 hours after intratracheal infection of neutropenic mice (A to C) or DKA mice (D and E), protected them from R. delemar infection. Survival of neutropenic 
(A) or DKA mice (D) was conducted using 10 mice per group with confirmed inhaled inoculum of 1.2 × 104 for (A) and 6.3 × 103 for (D). *P < 0.05 versus mice treated with 
preimmune IgG. A single dose of 30 g of anti-CotH3 IgG resulted in a significant reduction of lung and brain fungal burden in neutropenic (B) (inhaled inoculum of 
3.2 × 103) and DKA mice (E) (inhaled inoculum of 3.6 × 103) when compared to isotype-matched control IgG at the same dose. Mice were euthanized 72 hours after infec-
tion. Hematoxylin and eosin staining of lung and brain sections harvested from neutropenic mice (C) revealed extensive tissue edema and hemorrhage in the lungs of 
mice treated with isotype-matched IgG, whereas mice treated with anti-CotH3 IgG had normal architecture (lower magnification). Abundant fungal hyphae invading 
lungs of mice treated with isotype-matched IgG, but not anti-CotH3 IgG, could be detected (higher magnification). Brains from isotype-matched IgG-treated, but not 
anti-CotH3 IgG-treated, mice showed mucormycosis angioinvasion. Scale bars, 300 m (C).
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by hydrogen peroxide formed from superoxide, resulting in the for-
mation of a fluorescent product. A significant increase in ROS pro-
duction by PMN incubated with R. delemar occurred in the presence 
of anti-CotH3 IgG when compared to PMN incubated with the fungus 
alone or with the fungus and preimmune IgG (Fig. 4E).
A pathogen is recognized by the F(ab′)2 fragment of an antibody, 
while the Fc portion of the antibody is, in turn, identified and bound 
by immune cells such as neutrophils via the Fc receptors, which 
triggers activation of phagocytosis. To confirm the opsonophagocytic 
potential of anti-CotH3 IgG, we investigated the role of the anti-
body F(ab′)2 fragment and the Fc receptor in the ability of murine 
PMN to kill the fungus. The impact of Fc receptor blocking or the 
F(ab′)2 fragment on R. delemar killing by PMNs was measured using 
the XTT [2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium- 
5-carboxanilide] assay. While intact anti-CotH3 IgG enhanced mu-
rine PMN killing of R. delemar, blocking the PMN Fc receptor by 
antibodies completely abrogated fungal killing. Similarly, the use of 
F(ab′)2 fragments from CotH3 IgG did not enhance PMN-mediated 
killing of R. delemar over PMN incubated with the fungus in the 
presence of preimmune IgG (Fig. 4F). This finding shows that 
phagocytosis and subsequent killing of R. delemar spores by murine 
PMNs are triggered by anti-CotH3 IgG Fc fragment binding to the 
Fc receptor. These results also show that neutralization of CotH3 
antigen by the F(ab′)2 fragments is not sufficient to trigger PMN- 
mediated killing.
Collectively, these data show that anti-CotH3 antibodies en-
hance phagocytosis of R. delemar, which leads to enhanced growth 
inhibition via maturation of the phagolysosome and ROS produc-
tion. Therefore, the generated CotH3 IgGs are opsonophagocytic.
Because our in vitro and ex vivo data suggested an opsono-
phagocytic role for anti-CotH3 IgG, we investigated whether these 
antibodies protect by a similar mechanism in vivo. DKA mice were 
infected with R. delemar intratracheally. However, they were devoid 
of neutrophils by treatment with anti-Ly6G antibody (fig. S3). The 
lack of neutrophils in the DKA mouse model completely reversed 
the protective activity of anti-CotH3 antibodies (Fig. 4G), thus con-
firming the importance of their opsonophagocytic activity in vivo.
Monoclonal antibodies raised against CotH3 protect mice 
from pulmonary mucormycosis
Our encouraging results with polyclonal antibodies prompted us to 
generate mouse monoclonal antibodies against a 16-mer peptide of 
the CotH3 protein. Eight hybridoma cells were generated commer-
cially, and their antibodies were screened for their capacity to block 
R. delemar–mediated damage to HUVEC using 51Cr-release assay. 
Previously, we have found that polyclonal anti-CotH3 IgG blocks 
fungal-induced damage to these cells (18). Of the eight hybridomas, 
the antibodies from four clones (C1 to C4) were found to block 
R. delemar–induced endothelial cell damage (fig. S4) and were thus 
selected for expansion. One of the four clones (C4) died after several 
passages, whereas clones C1 to C3 grew robustly. The purified 
monoclonal antibody from these three clones (all IgG1) was tested 
for their capacity to prevent pulmonary mucormycosis in the DKA 
and neutropenic mice infected with R. delemar. In the DKA mice, 
all monoclonal IgG1s tested protected mice similarly to the poly-
clonal anti-CotH3 IgG (Fig. 5A). Monoclonal antibodies C1 and C2 
were tested in the neutropenic mice and significantly improved sur-
vival. Antibody C2 almost completely protected the neutropenic 
mice, significantly higher than the protection conferred by the poly-
clonal anti-CotH3 antibodies (Fig. 5B). Antibody C2 also recog-
nized native CotH3 of R. delemar and the rCotH3p by Western 
blotting (fig. S5). It also bound to different Mucorales and the poly-
clonal antibody (fig. S6).
Because of its superior activity and recognition of CotH on other 
Mucorales, the C2 antibody was chosen for further characterization of 
its protective activity against murine mucormycosis due to Mucorales 
Fig. 3. Anti-CotH3 antibodies protect neutropenic mice from infection by five other Mucorales. Neutropenic mice were infected intratracheally with Rhizomucor (A), 
Apophysomyces (B), Lichtheimia (C), Cunninghamella (D), or M. circinelloides (E) and then, 24 hours later, treated with 30 g of anti-CotH3 IgG or isotype-matched control 
IgG. Survival of mice served as an end point. Inhaled inocula were 1.6 × 103, 3.7 × 103, 4.6 × 103, 2.2 × 103 (average inoculum of two experiments), and 2.2 × 103 (average 
inoculum of two experiments) for Rhizomucor (A), Apophysomyces (B), Lichtheimia (C), Cunninghamella (D), or M. circinelloides (E), respectively. Ten mice per group were 
used, except for (D) and (E), in which 20 mice per group were used. *P < 0.05.
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Fig. 4. Anti-CotH3 antibodies stimulate immune recognition of R. delemar in vivo and in vitro through opsonophagocytosis. (A) Higher MPO levels detected in lungs 
and spleens harvested from DKA mice (n = 5 per group) infected with R. delemar (inhaled inoculum of 1.6 × 103 spores) and treated with 30 g of anti-CotH3 IgG versus 
preimmune IgG. Treatment with the antibodies started 24 hours after infection, and the mice were euthanized 72 hours after infection. Data are presented as raw MPO 
values in nanograms per gram of tissue or normalized to burden of infection in each individually marked organ in nano grams per gram per log10 colony-forming unit (CFU). 
(B) Anti-CotH3 IgG enhanced the ability of PMNs harvested from normal or DKA mice in phagocytizing R. delemar ex vivo. (C) Incubation of PMNs harvested from DKA with 
anti-CotH3 IgG, but not preimmune IgG, enhanced their ability to damage R. delemar ex vivo as determined using the XTT assay. (D) Confocal imaging using LysoTracker 
Red staining confirms the activation of PMN by anti-CotH3 IgG showing acidification and maturation of the phagolysosome after phagocytosis of the fungal spores. 
(E) Anti-CotH3 IgG-activated PMNs harvested from DKA mice generated significantly higher amounts of ROS compared to control conditions including PMNs alone, 
PMNs + R. delemar, or PMNs + R. delemar + preimmune IgG. Blocking of Fc receptors (Fc-R) of PMNs harvested from DKA mice with Fc receptor antibodies abrogates the 
ability of PMNs to damage R. delemar even in the presence of anti-CotH3 IgG. (F) Conversely, F(ab)′2 anti-CotH3 IgG fragments fail to enhance the DKA mouse PMN–mediated 
damage activity of R. delemar. (G) Neutrophil depletion by Ly6G antibody completely reverses the enhanced survival of DKA mice (n = 9 per group except for mice treated 
with anti- CotH3 IgG + Ly6G antibody, which had 8) infected with R. delemar and treated with anti-CotH3 IgG (given at 30 g 24 hours after infection). *P < 0.05 versus all 
groups, **P < 0.001 versus preimmune IgG, and P = 0.1 versus Ly6G antibody–treated mice. Data in (A) to (C), (E), and (F) are expressed as median ± interquartile changes.
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other than Rhizopus. A single 30-g dose of this antibody significantly 
reduced mortality in neutropenic mice infected with M. circinelloides 
and Lichtheimia (Fig. 5, C and D). These results support the devel-
opment of the C2 antibody as a novel immunotherapeutic approach 
to treat mucormycosis.
C2 IgG1 is synergistic with antifungal drugs in vivo
Any immunotherapeutic treatment is likely to be applied as an ad-
junctive therapy to antifungal drugs. Thus, we investigated the pro-
tective activity of combining the C2 antibody with two antifungal 
drugs that are commonly used to treat mucormycosis. We infected 
DKA mice intratracheally and treated them 48 hours later (to replicate 
clinically advanced disease) with a single 30-g dose of C2 with or 
without posaconazole (30 mg/kg) twice daily for 7 days. Posaconazole 
is often used for mucormycosis salvage therapy (25). As expected, 
the C2 antibody alone resulted in a reduced but significant protection 
when compared to mice given the monoclonal antibody 24 hours 
after infection (compare 50% survival in Fig. 6A to 70% survival in 
Fig. 5B). Posaconazole trended to enhance survival of DKA mice 
(33% survival) versus mice treated with isotype-matched control 
IgG1 (14% survival; P = 0.07). Impressively, all mice treated with 
the C2 antibody combined with posaconazole survived the infec-
tion (Fig. 6A) and appeared healthy at the termination of the study, 
and the lungs and brains harvested from surviving mice had no re-
sidual fungi as demonstrated by organ culturing. Concordant with 
these results, combination therapy significantly reduced the lung 
and brain fungal burden by 1 to 1.5 logs when harvested 72 hours 
after infection (Fig. 6, B and C).
We also evaluated the efficacy of combination therapy of the C2 
antibody with liposomal amphotericin B (LAmB), a drug that is the 
first-line therapy for mucormycosis (15). When therapy was initiated 
48 hours after infection, the mice receiving either the C2 antibody 
or LAmB as monotherapy had improved survival, which was statis-
tically significant for the mice treated with LAmB (56%; P = 0.005) 
but not the C2 antibody (P = 0.07). Mice treated with both the C2 
antibody and LAmB had 100% long-term survival, which was sig-
nificantly superior to that of mice receiving the control IgG (P = 0.0002) 
and the C2 antibody (P = 0.02), and trended to be better than the 
mice treated with LAmB (P = 0.05; Fig. 6D). Collectively, these re-
sults demonstrated that the C2 antibody significantly enhances the 
efficacy of currently used antifungals for treating mucormycosis.
DISCUSSION
We previously determined that Mucorales, including R. delemar, bind 
mammalian GRP78 via its cell surface fungal ligand CotH3, leading 
to HUVEC invasion and damage (18, 26). Repression of expression 
of either protein abrogates fungal-mammalian cell interaction and 
blocks fungal invasion and endothelial cell damage in vitro (18, 26). 
Inhibition of Rhizopus CotH3 expression prevents invasion even in 
mammalian cells overexpressing GRP78, highlighting the crucial role 
of this fungal protein in pathogenicity (18). In silico docking studies 
demonstrate that CotH3 conforms to a bimodal secondary structure 
that affords a complimentary and energetically favorable facet for 
binding to GRP78 (18). An important domain within this GRP78- 
binding region of CotH3 is predicted to be highly immunogenic 
and conserved among all medically important Mucorales, giving it the 
potential to be used for immunotherapeutic target. However, natural 
antibodies against CotH3 in healthy volunteers and in patients with 
mucormycosis are low. Thus, we reasoned that antibodies targeting 
Fig. 5. Monoclonal antibodies against CotH3 protect DKA and neutropenic mice from R. delemar and other Mucorales. Treatment with 30 g of three different 
clones of anti-CotH3 monoclonal antibodies (mAb) (C1 to C3), 24 hours after intratracheal R. delemar infection, protected DKA mice (n = 9 to 10 mice per group) (A) and 
neutropenic mice (n = 10 to 15 per group) (B) from lethal mucormycosis. *P < 0.05 versus isotype-matched control IgG; **P < 0.05 versus isotype-matched control IgG, C1 
clone, and polyclonal IgG. C2 clone also protected neutropenic mice from mucormycosis due to M. circinelloides (C) and L. corymbifera (D). n = 10 per group for mice in 
(C) and (D). Confirmed inhaled inocula were 5.6 × 103, 2.2 × 103, 1.6 × 103, and 2.1 × 103 for (A) to (D), respectively.
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CotH3 would be beneficial in treating murine mucormycosis, given the 
high importance of CotH proteins in the pathogenesis of mucormycosis 
(18, 19). Polyclonal antibodies raised against two peptides residing in 
the GRP78-binding region of CotH3 (18) not only prevented fungal 
adhesion/invasion to endothelial cells in vitro but also protected DKA 
mice from R. oryzae–associated pulmonary mucormycosis.
In this study, we confirmed that the anti-CotH3 polyclonal anti-
bodies protected by prevention of invasion and subsequent hema-
togenous dissemination, as indicated by the almost negligible spread 
of infection from the initial site of infection (lungs) to the secondary 
target organ (brain) in anti-CotH3 antibody-treated mice. This lack of 
dissemination was also apparent by lack of angioinvasion in organs 
collected from anti-CotH3 IgG-treated mice as early as 2 days after 
infection. The fact that polyclonal antibodies alone can interrupt 
hematogenous spread to the brain supported its further development 
as a potential immunotherapeutic drug. Among immunocompromised 
hosts, DKA and neutropenic patients represent the patients who are 
the most susceptible to mucormycosis (1, 3). Therefore, any novel 
therapy must demonstrate efficacy in both patient populations to be 
clinically and commercially viable. Here, we show that the protective 
effect of the anti-CotH3 antibodies extends to neutropenic mice, 
suggesting that antibody-based therapy is likely to be efficacious in 
both DKA and neutropenic patients. We found that the anti-CotH3 
IgG was highly protective when administered as a single dose of 30 g 
per mouse. This low dose of anti-CotH3 IgG is about 1.2 mg/kg, 
which is within the dosage range of 1 to 15 mg/kg of most monoclo-
nal antibodies that are approved for human use (27, 28).
Despite concordant studies showing an increase in mucormy-
cosis around the world (8–13), it is still a relatively rare disease. 
Therefore, any commercially viable therapy must target all Mucorales 
especially in the absence of a reliable rapid assay to identify the 
species of the infecting fungus in patients with mucormycosis. 
CotH proteins are universally present in Mucorales but absent in 
other medically important organisms. This property makes them 
a desirable target for the development of specific therapy for mu-
cormycosis. In addition, a 16-mer peptide sequence of CotH3 that 
was used for developing monoclonal antibody–based therapy is 
highly conserved among Mucorales with >70% amino acid identity, 
is surface- exposed, and, importantly, resides in the binding func-
tional facet of the protein. Because of these desirable attributes, 
antibodies raised against this region recognized all Mucorales strains 
tested in vitro and demonstrated protective efficacy in mice. Although 
treatment with anti-CotH3 antibodies alone prolonged survival in 
mice infected with all strains of Mucorales tested, the extent of pro-
tection varied with the strain of Mucorales and was never 100%. How-
ever, when the lead C2 monoclonal antibody was combined with 
conventional antifungal agents, 100% of the mice survived with no 
evidence of residual infection, possibly leading to sterilizing immunity. 
Fig. 6. C2 monoclonal IgG1 synergistically protects DKA mice from R. delemar when combined with antifungal drugs. DKA mice were infected with R. delemar 
(confirmed inhaled inoculum of 3.9 × 103) and, 48 hours later, treated with either a single dose of 30 g of C2 monoclonal IgG1, posaconazole (POSA) (30 mg/kg, twice 
daily) for 7 days, or a combination of both. End points were survival (A) (n = 9 to 14 per group) or tissue fungal burden in lungs (B) or brain (C) as determined by quantitative 
polymerase chain reaction (PCR). (D) The same model was used with similar treatment except that posaconazole treatment was substituted with LAmB (10 mg/kg per day for 
4 days) (n = 9 to 10 per group). *P < 0.05 versus isotype-matched IgG, **P < 0.008 versus all other arms, ‡P < 0.006 versus isotype-matched IgG, ¥P < 0.03 versus isotype- 
matched IgG or C2, and P = 0.05 versus LAmB.
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These promising results suggest that combination therapy with the 
C2 antibody and conventional antifungal agents will likely be ef-
fective against multiple members of the Mucorales family.
The anti-CotH3 antiserum protects mice against mucormycosis 
by multiple mechanisms. Previously, we found that it inhibited the 
capacity of Mucorales to invade and damage host cells in vitro. Anti-
bodies protect against infection by neutralizing virulence factors 
(28), directly inhibiting and/or killing the targeted organism (29), 
and/or enhancing clearance of the infecting organism by phago-
cytes (30). Here, we found that treatment of DKA mice with the anti- 
CotH3 antibodies resulted in an 8- to 20-fold increase in MPO 
content in the spleen and lungs, indicating that the antibody also 
enhances phagocyte recruitment. In addition, the polyclonal anti- 
CotH3 antibodies augmented neutrophil and peritoneal macro-
phage killing of R. delemar ex vivo in an Fc-dependent manner. As 
expected, the enhanced phagocytosis of R. delemar in the presence 
of anti-CotH3 antibodies was accompanied by increased acidifica-
tion of phagolysosome, enhanced ROS production, and augmented 
killing of the fungus. These properties may be especially beneficial 
in patients who are in DKA, whose phagocytes have reduced capacity 
to recognize and clear Mucorales (31). Reducing the number of cir-
culating neutrophil by anti-Ly6G antibody in the DKA mice re-
versed the protective effect seen with the anti-CotH3 antibodies to 
a level that is even worse than mice treated with preimmune IgG. These 
data emphasize the role of anti-CotH3 in enhancing neutrophil func-
tion in the DKA host.
A notable finding was that the anti-CotH3 antibodies also pro-
tected neutropenic mice from mucormycosis. One possible explana-
tion for this result is that the antiserum enhanced the capacity of 
fungicidal activity of macrophages in vivo. Although administration 
of cyclophosphamide to mice results in complete pancytopenia, it 
has a lesser effect on tissue macrophages, which are usually derived 
from an embryonic, and not from hematopoietic, origin (32). These 
results suggest that the anti-CotH3 antibodies would likely be effective 
in neutropenic patients. Future studies to decipher the role of phago-
cytes in protection afforded by anti-CotH3 antibodies using trans-
genic mice (e.g., p47phox−/− CD11c-depleted mice) are underway.
The use of monoclonal antibodies in clinical application is supe-
rior to polyclonal antibodies owing to providing unlimited supply 
of antibodies with consistency in efficacy, production, as well as 
pharmacokinetic-pharmacodynamic and toxicity profiles (33). We were 
able to isolate several monoclonal antibodies that prevented invasion 
and damage of HUVECs in vitro and showed similar or superior 
activity to polyclonal anti-CotH3 antibodies in protecting DKA and 
neutropenic mice. Our lead monoclonal IgG1 (C2) performed better 
against other Mucorales such as M. circinelloides and Lichtheimia, 
with higher survival rates of mice compared to survival rates of in-
fected mice treated with polyclonal antibodies or control IgG. Of 
critical clinical importance is the remarkable effectiveness of treat-
ment of the C2 antibody in combination with either posaconazole or 
LAmB, even when therapy was initiated after 48 hours of infection. The 
capacity of the C2 antibody to enhance the efficacy of posaconazole 
was especially notable as this drug has only modest activity (10 to 
30% survival) in the DKA mouse model when used as a single agent (21).
In summary, we show that antibodies targeting CotH proteins 
represent an effective and reliable novel therapy, especially when 
combined with currently approved drugs for the treatment of mu-
cormycosis. The mechanism of action of these antibodies includes 
prevention of invasion, enhanced phagocyte recruitment, and in-
creased fungal clearance via enhanced opsonophagocytosis. Our 
future studies are focused on producing an equally efficacious hu-
manized version of the C2 monoclonal antibodies and developing a 
viable cell line that will produce the humanized version of the anti-
body in commercial quantities. Achieving this goal would enable 
manufacturing, toxicity studies, and clinical trials to determine the 
efficacy of the humanized anti-CotH3 antibody as adjunctive therapy.
MATERIALS AND METHODS
Organisms and culture conditions
R. delemar 99-880 (formerly classified as R. oryzae), R. oryzae 99-892, 
M. circinelloides f. jenssenii UTHSCSA DI15-131, and M. ramosissimus 
97-1192 are clinical isolates obtained from the Fungus Testing Lab-
oratory at the University of Texas Health Sciences Center at San 
Antonio (UTHSCSA). C. bertholletiae 182, also a clinical isolate, was 
a gift from T. Walsh (Weill Cornell Medical College of Cornell Uni-
versity, New York, NY, USA). L. corymbifera is another clinical isolate 
obtained from the DEFEAT Mucor clinical study (34). Apophysomyces 
ATCC 90757 was obtained from the American Type Culture Collec-
tion (ATCC; Manassas, VA), while Rhizomucor was obtained from a 
patient seen at Harbor-UCLA (University of California at Los Angeles) 
Medical Center. A. fumigatus AF293 was used for CotH3 antibody 
binding studies. All organisms were grown on potato dextrose agar 
(PDA; BD Diagnostic, NJ) plates by sprinkling silica beads that have 
been absorbed with spore suspension of each organism. The plates 
were incubated at 37°C for 4 to 7 days for Mucorales and 14 days for 
A. fumigatus until sporulation is apparent on confluent growth plates.
Spores were collected in endotoxin-free Dulbecco’s phosphate- 
buffered saline (PBS) containing 0.01 or 0.2% Tween 80 for Mucorales 
or Aspergillus, respectively. Collected spores were washed with PBS 
and counted with a hemocytometer to prepare the final inocula. To 
form germlings, spores were incubated in liquid yeast extract–peptone– 
dextrose [YPD; 1% yeast extract (Difco Laboratories, Detroit), 2% Bacto 
Peptone (Difco Laboratories), and 2% glucose (Sigma- Aldrich, St. Louis)] 
medium at 37°C with shaking for 3 hours.
Saccharomyces cerevisiae BJ5464 (ATCC) was used for rCotH3p 
production and was routinely cultured on YPD medium. When 
transformed with CotH3, it was grown on yeast nitrogen base (YNB) 
medium supplemented with ammonium sulfate without uracil.
Antibody binding assay
Rabbit polyclonal antibodies targeting two peptides (MGQTNDGAY-
RDPTDNN and GAGKKHNNAKQSWNW) or mouse monoclonal 
antibodies against the CotH3 peptide MGQTNDGAYRDPTDNN were 
commercially obtained from ProMab Biotechnologies (Richmond, 
CA). R. delemar spores or germlings (100 l of 5 × 105 cells/ml) were 
incubated for an hour on ice with CotH3 purified IgG (3 to 100 g/ml), 
monoclonal antibodies (100 g/ml), or preimmune IgG (100 g/ml). 
For the polyclonal antibodies, the cells were counterstained with 
anti-rabbit IgG–fluorescein isothiocyanate (FITC) conjugated or 
control IgG–FITC (eBioscience) for another hour on ice. For the 
monoclonal antibody binding, the cells were counterstained similar 
to polyclonal antibodies as previously, with the exception of using 
anti-mouse IgG–FITC or its respective control IgG–FITC (BD Bio-
sciences). The cells were rinsed twice with staining buffer [2% fetal 
bovine serum (FBS) (Gibco, Thermo Fisher Scientific, Waltham, MA) 
in PBS] before determining the binding capacity of the antibodies 
using a FACSCalibur (Becton Dickinson) instrument equipped 
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with an argon laser emitting at 488 nm. Fluorescence emission was 
read with a 515/40 band-pass filter. Fluorescence data were collected 
with logarithmic amplifiers. The population percent fluorescence of 
104 events was calculated using the CellQuest software.
Polyclonal and monoclonal antibody preparation
Rabbit IgG antibodies were purified from rabbits before (preimmune 
IgG) or after immunization with the CotH3 peptides (anti-CotH3 
IgG) by protein A/G spin column (Thermo Fisher Scientific) 
according to the manufacturer’s instructions. Monoclonal CotH3 
hybridoma cells were propagated in WHEATON CELLine bioreactor 
350 using protein-free hybridoma medium 1× (Gibco) for 5 to 7 days 
at 37°C in 5% CO2. The supernatant containing monoclonal anti-
body was collected and purified using protein G spin column (Thermo 
Fisher Scientific). The antibodies were dialyzed in PBS using a dial-
ysis cassette (Thermo Fisher Scientific), and the purity of the anti-
body was confirmed by SDS–polyacrylamide gel electrophoresis 
(PAGE) before determining the concentration using the Bradford 
protein assay (Bio-Rad, Hercules, CA). Endotoxin level measured 
by a Limulus Amebocyte Lysate (LAL) kit (Charles River Laboratories) 
was determined to be <0.8 endotoxin units (EU)/ml for polyclonal 
antibodies and <0.4 EU/ml for monoclonal antibodies, which are 
below the body weight (5 EU/kg) set for intraperitoneal injection (35).
rCotH3p production and Western blot
The Flag tag–CotH3 construct was created using the yeast plasmid 
pXW55-URA3. To generate the pXW55-FLAG-TEV-CotH3-URA3 
[8063–base pair (bp)] construct, 1705-bp CotH3 complementary 
DNA (cDNA) was synthesized from R. delemar 99-880 using an RNA 
extraction kit (Qiagen, Hilden, Germany) and a cDNA synthesis kit 
(Promega, Madison, WI) according to the manufacturers’ instruc-
tions. The synthesized CotH3 cDNA was flanked by Flag-TEV sequences 
at the 5′ end using polymerase chain reaction (PCR) and then sub-
cloned into the Spe I and Pml I cloning site. The constructed vector was 
transformed into S. cerevisiae BJ5464, and the positive colonies were 
selected on uracil-free YNB medium. The positive yeast colonies 
containing the right constructs appeared after incubation for 3 days 
at 30°C, which were then confirmed by PCR and sequencing.
To produce the rCotH3p, a clone was grown in YPD medium at 
30°C for 3 days with shaking at 200 rpm. The cells were centrifuged 
and the pellet was washed with tris-buffered saline (TBS) before sus-
pending in a small volume of cold TBS. Suspended yeast cells were 
then disrupted by sonication for 30 min with 1-min intervals inter-
rupted with 1-min storing on ice. The lysate was then centrifuged at 
10,000g for 30 min. The collected supernatant was filtered through 
a 0.20-m filter, followed by purification using anti-Flag magnetic 
beads (Sigma-Aldrich) according to the manufacturer’s instructions. 
The purity of CotH3 protein was measured by SDS-PAGE gel, fol-
lowed by Western blotting using a mouse CotH3 monoclonal anti-
body (1:1000) and an anti-mouse IgG–horseradish peroxidase (HRP) 
antibody (1:3000) as a secondary antibody. Endotoxin level was 
measured by LAL as above. The use of yeast as an expression system 
provided endotoxin-free protein.
To detect the expression of CotH3 on R. delemar, spores (5 × 107) 
were grown in YPD medium overnight at 37°C. Mycelia were col-
lected by filtration, washed briefly with PBS, and then ground thor-
oughly in liquid nitrogen using pestle and mortar for 3 min. The 
ground powder was immediately transferred to a microfuge tube 
containing 500 l of extraction buffer that consisted of 50 mM tris-HCl 
(pH 7.5), 150 mM NaCl, and 10 mM MgCl2. The extraction buffer 
was supplemented with 1× Halt Protease Inhibitor Cocktails (Ther-
mo Fisher Scientific). The sample was vortex-mixed vigorously for 
1 min and then centrifuged for 5 min at 21,000g at 4°C. The su-
pernatant was transferred to a new tube, and the protein concentra-
tion was determined using the Bradford method.
Human anti-CotH3 antibodies
To determine the level of natural anti-CotH3 antibodies, we collected 
sera from 12 healthy volunteers who routinely work with Mucorales 
and 11 patients diagnosed with definitive mucormycosis by either 
histology or cultures. The volunteer and patient samples were 
obtained at the Los Angeles Biomedical Research Institute at 
Harbor-UCLA Medical Center or Stanford University under an insti-
tutional review board (IRB)–approved protocol. Some of the patient 
samples were sequentially taken from the same patient following 
initial diagnosis (1 to 72 days after diagnosis). Anti-CotH3 antibody 
titers were measured using ELISA in 96-well plates. Each well was 
coated with either rCotH3p (100 l of 5 g/ml) in PBS or the 16-mer 
antigenic peptide dissolved in carbonate-bicarbonate buffer. Human 
sera were incubated for 1 hour at room temperature following a 
blocking step with PBS containing 3% bovine serum albumin. The 
wells were washed three times with PBS containing 0.05% Tween 
20, followed by another three washes with PBS. Goat anti-human 
secondary antibody conjugated with HRP (Sigma-Aldrich) was added 
at a final dilution of 1:5000, and the plate was further incubated for 
1 hour at room temperature. Wells were washed with PBS and in-
cubated with the substrate containing 0.1 M citrate buffer (pH 5.0), 
50 mg of o-phenylenediamine (Sigma-Aldrich), and 10 l of 30% 
H2O2. The color was allowed to develop for 30 min, after which the 
reaction was terminated by addition of 3 N HCl and the optical den-
sity (OD) at 490 nm was determined in a microtiter plate reader. 
Negative control wells received only diluent, and background ab-
sorbance was subtracted from the test wells to obtain final OD read-
ings. The ELISA titer was taken as the reciprocal of the last serum 
dilution that gave a positive OD reading (i.e., more than the mean 
OD of negative control samples plus two SDs).
Endothelial cell propagation and damage assay
Human umbilical vein endothelial cells (HUVEC) were collected by 
the method of Jaffe et al. (36). Cells were harvested using collagenase 
and grown in M-199 (Gibco) enriched with 10% FBS, 10% defined 
bovine calf serum, l-glutamine, penicillin, and streptomycin (all from 
Gemini Bio-Products, Sacramento, CA). Second-passage cells were 
grown to confluence in 96-well tissue culture plates (Corning Costar, 
NY) on fibronectin (BD Biosciences). All incubations were in 5% CO2 
at 37°C. All propagations were conducted under endotoxin-free con-
ditions [concentration of <0.01 IU/ml as determined by a chromo-
genic LAL assay (BioWhittaker Inc., Walkersville, MD)].
To screen for protective monoclonal antibodies, the HUVEC dam-
age assay using radiolabeled chromium (51Cr) was used (37). Briefly, 
HUVECs grown in 96-well tissue culture plates containing detach-
able wells were incubated with Na251CrO4 (1 Ci per well) in M-199 
medium for 16 hours. Excess 51Cr was aspirated, and wells were 
washed twice with prewarmed Hanks’ balanced salt solution (HBSS; 
ScienCell Research Laboratories, Carlsbad, CA). Cells were infected 
with fungal germlings (1.0 × 106 ml germinated for 1 hour at 37°C 
with 50 to 100 g of the tested antibody) suspended in 200 l of dex-
trose minimal essential medium (DMEM; Thermo Fisher Scientific) 
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supplemented with 50 or 100 g of the tested monoclonal anti-
body, purified CotH3 polyclonal IgG [as a positive control because 
we reported that these polyclonal antibodies block HUVEC damage 
(18)], or isotype-matched control IgG. Spontaneous 51Cr release was 
determined by incubating HUVECs in DMEM without R. delemar but 
with each of the tested antibody (to determine toxicity). After 4 hours 
of incubation at 37°C in a 5% CO2 incubator, 50% of the medium 
was aspirated from each well and transferred to glass tubes, and 
cells were manually detached and placed into another set of tubes. 
The amount of 51Cr in the aspirate and the detached well was deter-
mined by gamma counting. The total amount of 51Cr incorporated 
by endothelial cells in each well was calculated as the sum of radio-
active counts per minute of the aspirated medium and radioactive 
counts of the corresponding detached wells. After data were cor-
rected for variations in the amount of tracer incorporated in each 
well, the percentage of specific endothelial cell release of 51Cr was 
calculated as follows: [(experimental release × 2) − (spontaneous 
release × 2)]/[total incorporation − (spontaneous release × 2)]. Each 
experimental condition was tested at least in triplicate, and the ex-
periment was repeated at least once.
Mouse models
Two mouse models were used in these studies: (i) the DKA and (ii) 
the neutropenic mice. Both models used male ICR mice (20 to 23 g) 
obtained from Envigo (NJ). For the DKA model, mice were injected 
with a single intraperitoneal dose of streptozotocin (210 mg/kg; Sigma- 
Aldrich) in 0.2 ml of Na citrate buffer 10 days before infection, as 
described previously (21). Glycosuria and ketonuria were confirmed 
in all mice 7 days after streptozotocin treatment. In addition, on days −2 
and +3 relative to infection, DKA mice were given a dose of cortisone 
acetate (250 mg/kg) by subcutaneous injection. For the neutropenic 
model, mice were injected with cyclophos phamide (200 mg/kg, given 
intraperitoneally) and cortisone acetate (500 mg/kg, given subcuta-
neously) on days −2 and +3 relative to infection (21).
Mouse PMNs were isolated from peripheral blood cells of DKA 
or normal mice after heparinization using dextran sedimentation 
followed by Ficoll-Paque (GE Healthcare, Chicago, IL), as described 
(38). After removing contaminating erythrocytes by hypotonic lysis, 
the neutrophils were washed, counted with a hemocytometer, and 
resuspended at the appropriate concentration with downstream assay 
solution or medium. Neutrophils were kept on ice until use, within 
an hour of collection.
For the DKA mice depleted of neutrophils, mice were injected in-
traperitoneally with anti-mouse Ly6G (1A8 clone) antibody (4 mg/kg) 
(BioLegend) on days −2, 0, +2, and +4 relative to intratracheal chal-
lenge with R. delemar as above. Neutrophil depletion was confirmed by 
microscopically counting circulating neutrophils in ~50 l of sam-
ples collected from the mice tail veins using Wright-Giemsa stain-
ing. The Ly6G antibody treatment resulted in neutropenia for at 
least days +4 to +6 (fig. S3).
Peritoneal macrophage collection
ICR mice (6 weeks old) were euthanized by cervical dislocation. 
Each mouse was cleaned with 70% alcohol, and the abdominal skin 
was removed with sterile scissors to expose the intact peritoneal wall. 
The peritoneum was then injected with 10 ml of cold PBS without 
calcium and magnesium with 5 mM EDTA using a 20-gauge needle 
syringe. The mouse was slightly shaken for 1 min, followed by har-
vesting the peritoneal fluid slowly with the same syringe. The peri-
toneal fluid was then transferred into a 50-ml conical tube, which 
was kept on ice while washing three times with cold PBS buffer. The 
cells were resuspended in RPMI 1640 with 10% FBS at a concentra-
tion of 2 × 105 cells/ml before transferring them to a six-well plate 
(5 ml per well). The plate was incubated for 6 hours at 37°C with 5% 
CO2 to allow macrophages to adhere to the surface of the plate. 
Nonadherent cells were removed, and the remaining cells repre-
sented >90% macrophages. The cell concentration was adjusted in 
HBSS before performing the ex vivo assay.
Infection and treatment
Immunosuppressed mice were infected intratracheally with 25 l of 
PBS containing 2.5 × 105 spores of each Mucorales (inoculum for 
M. circinelloides was 2.5 × 106 spores). Immediately after challenge, 
two mice from each group infected with different Mucorales were 
euthanized and their lungs were homogenized in PBS and quantita-
tively cultured on PDA plates containing 0.1% Triton X-100. Colonies 
were counted after 24-hour incubation period at 37°C. After infection, 
mice were treated daily with 5 mg in 0.2 ml of irrigation water of 
ceftazidime subcutaneously to prevent bacterial superinfection (21). 
Antibody treatment with a single dose of 30, 100, or 300 g of poly-
clonal CotH3 purified IgG, preimmune polyclonal purified IgG, CotH3 
monoclonal antibody, or isotype-matched control mouse IgG (Bio 
X Cell) started 24 or 48 hours after infection and was administered by 
intraperitoneal injection. Time to moribundity (equated with survival) 
served as the primary end point.
As a secondary end point and in some experiments, fungal burden 
in the lungs and brains (primary and secondary target organs) (21) 
was determined 72 hours after infection by quantitative PCR assay, 
as we previously described (39). Values were expressed as log10 spore 
equivalent per gram of tissue. Histopathological examination was 
carried out on sections of the harvested organs after fixing in 10% 
zinc formalin. The fixed organs were embedded in paraffin, and 
5-mm sections were stained with hematoxylin and eosin (40).
For determining the protective activity of the monoclonal anti-
bodies with antifungal drugs, DKA mice were infected as described 
and treated with the monoclonal antibody posaconazole (Merck 
and Co., Kenilworth, NJ), LAmB (Gilead Sciences, Foster City, CA), 
or a combination of the monoclonal antibody and either antifungal 
drug started 48 hours after infection. Monoclonal antibody was 
given once by intraperitoneal injection at 30 g, posaconazole was 
administered by oral gavage at 30 mg/kg twice daily for 7 days, 
and LAmB was given intravenously at 10 mg/kg per day for 4 days. 
Time to moribund state and tissue fungal burden served as end 
points as above.
Mouse MPO assay
To determine the level of PMN recruitment to site of infection and 
the effect of antibody treatment on this recruitment, we used the MPO 
ELISA Kit (Abcam, Cambridge, UK). Tissue homogenate collected from 
organs processed for tissue fungal burden as described (to correlate 
the data of PMN recruitment to tissue fungal burden and reduce the 
number of mice used) was processed according to the manufacturer’s 
instructions. Results were expressed as the amount of MPO per gram 
of tissue or MPO per gram per colony-forming unit (CFU) (41).
PMN phagocytosis assay
To investigate the phagocytic activity of mouse PMNs collected 
from normal or DKA mice and the effect of anti-CotH3 polyclonal 
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IgG on this process, fungal spores were stained with Alexa Fluor 
488 carboxylic acid (Thermo Fisher Scientific) for 60 min on ice and 
then incubated with PMNs (1:20, PMNs/R. delemar) at 37°C for 30 min 
before the cells were quantified by flow cytometry (42). PMNs con-
taining phagocytized organisms were identified by size and fluores-
cence as described.
Growth inhibition assay
Inhibition of growth of R. delemar by PMN from DKA mice was 
conducted using the XTT assay (38). R. delemar spores were col-
lected and washed twice with HBSS. Fifty-eight microliters of 
PMNs (3.4 × 105 cells/ml) and 100 l of R. delemar (1 × 105 cells/ml) 
were cocultured in 96-well flat-bottom plates at 37°C for 2 hours 
with 10% heat-inactivated mouse serum (2:1, PMNs/R. delemar) 
with or without preimmune IgG or anti-CotH3 IgG. Next, the 
plate was stored overnight at 4°C to lyse all the PMNs. Forty mi-
croliters of XTT (1 mg/ml; Sigma-Aldrich) and 2 l of 0.625 mM 
menadione solution (Sigma- Aldrich) were added to the 96-well 
plates to allow the conversion of the XTT to its formazan deriva-
tive (43). The plate was shaken for 1 to 2 min at 100 rpm until 
complete dissolution of the formazan derivatives. The plate was 
incubated at 37°C for additional 6 hours before the XTT conver-
sion was measured using a Dynex MRX Revelation microtiter plate 
reader (BioSurplus, San Diego, CA) at OD at 450 nm. XTT conver-
sion by metabolically active cells was calculated after subtracting 
the background OD of simultaneously incubated wells containing 
media and reagents without spores.
Fc receptor and F(ab′)2 blocking assay
To determine the role of the Fc receptor in promoting anti-CotH3 
antibody-mediated PMN phagocytosis and growth inhibition of 
R. delemar spores, we conducted the growth inhibition assay as de-
scribed above but with inclusion of antibodies (3 g/ml; BD Biosciences) 
targeting the Fc receptor. We also evaluated the role of F(ab′)2 frag-
ments purified from anti-CotH3 IgG in inducing the inhibition of 
R. delemar spores by PMNs collected from DKA mice (44). F(ab′)2 
fragments from anti-CotH3 IgG were purified with the Pierce 
F(ab′)2 Preparation Kit (Thermo Fisher Scientific) according to the 
manufacturer’s instruction. The inhibition assay was conducted as 
above using the same assay parameters.
Lysosome staining
A LYSO-ID Red lysosomal detection kit (Enzo Life Sciences, Farmingdale, 
NY) was used for the lysosome detection in PMNs or macrophages. 
Lysosomal staining was performed according to the manufacturer’s 
recommendations. Briefly, PMNs or macrophages collected from 
DKA mice were suspended in 250 l of HBSS with 10% mouse 
heat-inactivated serum at a concentration of 2 × 106 cells/ml. 
The phagocytes were incubated with or without 250 l of R. delemar 
spores and R. delemar spores + either preimmune IgG or anti- 
CotH3 IgG (3 g/ml) for 30 min at 37°C with gentle shaking 
(1 rpm). A LYSO-ID Red detection reagent (0.5 l) (Enzo Life 
Sciences) and Hoechst 33342 nuclear stain (0.5 l) were added to 
500 l of cells. The samples were then incubated for an additional 
30 min at 37°C and washed with 100 l of 1× assay buffer. The 
stained cells were imaged with a Leica confocal microscope using 
a Texas Red filter set for lysosomal imaging and a 4′,6-diamidino- 2-
phenylindole (DAPI) filter set for Hoechst 33342 staining nuclear 
imaging.
Assessment of ROS
The ability of anti-CotH3 purified polyclonal IgG to stimulate super-
oxide production by PMNs collected from DKA mice was assessed 
ex vivo using DHR123 dye. This technique relies on the induction of 
fluorescence of DHR in the presence of ROS. Briefly, PMNs incubated 
with R. delemar (1:2, PMN/R. delemar spores) with anti-CotH3 IgG 
or isotype-matched IgG (3 g/ml) were incubated in the dark at 
37°C for 25 min in the presence and absence of 100 M DHR123 
(Molecular Probes, Eugene, OR) in prewarmed HBSS with Ca/Mg 
(ScienCell Research Laboratories, Carlsbad, CA). The cells were then 
analyzed for size and fluorescence with a FACSCalibur instrument 
(Becton Dickinson) within 30 min after DHR staining, as described 
above.
Statistical analysis
Statistical analysis was carried out by the nonparametric log-rank 
test for survival studies or Wilcoxon rank sum test for the rest of the 
comparisons. For all comparisons, a P value of <0.05 was considered 
significant.
Study approval
Animal studies were approved by the Institutional Animal Care and 
Use Committee of the Los Angeles Biomedical Research Institute at 
Harbor-UCLA Medical Center, according to the NIH guidelines for 
animal housing and care. Human endothelial cell collection was ap-
proved by the IRB at Los Angeles Biomedical Research Institute at 
Harbor-UCLA Medical Center. Sera from healthy volunteers or 
mucormycosis patients were collected using an IRB-approved protocol 
and tested for CotH3 antibody titers at LA BioMed (protocol #11671).
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